disopyramide has been researched along with Kidney Diseases in 9 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Postmarketing drug surveillance revealed the occurrence of hypoglycemia associated with the use of disopyramide phosphate (Norpace) for the control of ventricular arrhythmias." | 9.05 | Hypoglycemia in patients receiving disopyramide phosphate. ( Cohen, A; Nitzberg, DM; Schubert, EN; Strathman, I, 1983) |
| "Disopyramide is a new antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide." | 6.36 | Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978) |
| "Postmarketing drug surveillance revealed the occurrence of hypoglycemia associated with the use of disopyramide phosphate (Norpace) for the control of ventricular arrhythmias." | 5.05 | Hypoglycemia in patients receiving disopyramide phosphate. ( Cohen, A; Nitzberg, DM; Schubert, EN; Strathman, I, 1983) |
| "Disopyramide is a new antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide." | 2.36 | Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. ( Avery, GS; Brogden, RN; Heel, RC; Speight, TM, 1978) |
| "Disopyramide kinetics were studied in 30 patients with normal to severely impaired renal function (endogenous creatinine clearance 7." | 1.27 | Disopyramide kinetics in renal impairment: determinants of interindividual variability. ( Burk, M; Peters, U, 1983) |
| " After an oral dose in healthy volunteers the plasma elimination half-life of total disopyramide was 8." | 1.26 | The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans. ( Aitio, ML; Allonen, H; Kanto, J; Mäntylä, R, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Strathman, I | 1 |
| Schubert, EN | 1 |
| Cohen, A | 1 |
| Nitzberg, DM | 1 |
| Kumana, CR | 1 |
| Rambihar, VS | 1 |
| Willis, K | 1 |
| Gupta, RN | 1 |
| Tanser, PH | 1 |
| Cairns, JA | 1 |
| Wildeman, RA | 1 |
| Johnston, M | 1 |
| Johnson, AL | 1 |
| Gent, M | 1 |
| Burk, M | 1 |
| Peters, U | 1 |
| Aitio, ML | 1 |
| Allonen, H | 1 |
| Kanto, J | 1 |
| Mäntylä, R | 1 |
| Desai, JM | 1 |
| Scheinman, MM | 1 |
| Hirschfeld, D | 1 |
| Gonzalez, R | 1 |
| Peters, RW | 1 |
| Hanada, K | 1 |
| Odaka, K | 1 |
| Kudo, A | 1 |
| Ogata, H | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Wood, M | 1 |
| Nanni, G | 1 |
| Magalini, SC | 1 |
| Serino, F | 1 |
| Castagneto, M | 1 |
2 reviews available for disopyramide and Kidney Diseases
| Article | Year |
|---|---|
Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Disopyramide; Drug Interactions; Electrophysiology; Heart; Hemodynamics; Human | 1978 |
Plasma drug binding: implications for anesthesiologists.
Topics: Age Factors; Alfentanil; Alprenolol; Anesthesia; Anesthetics; Blood Proteins; Bupivacaine; Burns; Ca | 1986 |
2 trials available for disopyramide and Kidney Diseases
| Article | Year |
|---|---|
Hypoglycemia in patients receiving disopyramide phosphate.
Topics: Aged; Blood Glucose; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Disopyramide; | 1983 |
Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction.
Topics: Adult; Aged; Arrhythmias, Cardiac; Body Weight; Clinical Trials as Topic; Disopyramide; Double-Blind | 1982 |
5 other studies available for disopyramide and Kidney Diseases
| Article | Year |
|---|---|
Disopyramide kinetics in renal impairment: determinants of interindividual variability.
Topics: Adult; Aged; Creatinine; Disopyramide; Dose-Response Relationship, Drug; Drug Evaluation; Female; He | 1983 |
The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Topics: Administration, Oral; Adult; Disopyramide; Female; Humans; Hydrogen-Ion Concentration; Injections, I | 1982 |
Cardiovascular collapse associated with disopyramide therapy.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Disopyramide; Electrocardiography; Female; Heart A | 1981 |
Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Topics: Animals; Anti-Arrhythmia Agents; Antineoplastic Agents; Area Under Curve; Biotransformation; Blood U | 1999 |
Effect of disopyramide in a cyclosporine-treated patient.
Topics: Adult; Cyclosporins; Disopyramide; Drug Synergism; Female; Humans; Kidney Diseases; Kidney Transplan | 1988 |